Miranda MZ, Mulet PAM, Gámez EMM, Escobar BA, Rodríguez DM, López AG

Language: Spanish
References: 24
Page: 63-75
PDF size: 438.21 Kb.

ABSTRACT

Introduction: Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs (NSAIDs) are two independent risks factors mostly involved in the etio-pathogenesis of gastrointestinal mucosal damage. A possible interaction between them, influencing the magnitude of the chronic antral gastritis, is controversial.
Objective: to estimate histopathological aspects of chronic antral gastritis due to Helicobacter pylori, either in association or not with nonsteroidal anti-inflammatory drugs consumption.
Method: a case-control study in which the universe was conformed by 282 patients on whom an endoscopic antral biopsy was performed. It took place at Vladimir I. Lenin Hospital, from February 2008 to February 2009. Ninety one patients with histological diagnosis of Helicobacter pylori chronic antral gastritis constituted the sample of the study, 32 of them were non-steroidal anti-inflammatory drugs users (study group), and 59 were not (controls).
Results: although 81.25 % in the study group had chronic active gastritis, this was prevalent in controls (Z=2.085; p‹0.05). 59.37 % of the study group showed mild severity inflammation, with a statistically significant greater proportion of moderate to severe lesions in controls (Z=4.568; p‹0.001). Moderate to high Helicobacter density was observed in 53.13 % of the study group, with no significant differences with respect to controls (Z=0.889; p›0,05).
Conclusions: the prevalence of the activity and moderate to severe inflammation in antral chronic gastritis due to Helicobacter pylori in non-consumers of non-steroidal anti-inflammatory drugs might be hypothetically attributed to both the anti-inflammatory action as well as a protective effect of the gastric mucosa exerted by non-steroidal anti-inflammatory drugs in patients taking these drugs. The colonization density does not appear to be significantly influenced by these drugs.

REFERENCES

1. Valdivia Roldán M. Gastritis y Gastropatías. Rev Gastroenterol Perú. 2011 [citado 12 jun 2014]; 31(1):38-48. Disponible en: http://www.scielo.org.pe/pdf/rgp/v31n1/a08v31n1.pdf

2. Musumba C, Jorgensen A, Sutton L, Van Eker D, Moorcroft J, Hopkins M, et al. The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther. 2012 [citado 12 jun 2014]; 36:48-56. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2012.05118.x/pdf

3. Hart J, Hawkey CJ, Lanas A, Naesdal J, Talley NJ, Thomson AB, et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2010 [citado 12 jun 2014]; 31:143-9. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2009.04133.x/pdf

4. Mulet Pérez A, Gámez Escalona M, Medina Menéndez FM, Mulet Gámez AM. Gastritis Crónica Antral por Helicobacter pylori asociada o no a úlcera duodenal. CCM. 2005 [citado 13 jun 2014]; 9(2). Disponible en: http://www.cocmed.sld.cu/no92/n92ori10.htm

5. Gámez Escalona M, Mulet Pérez A, Gamboa Figueredo J, Mulet Gámez A. Gastritis crónica antral por Helicobacter pylori asociada o no a úlcera gástrica. CCM. 2005 [citado 13 jun 2014]; 9(3). Disponible en: http://www.cocmed.sld.cu/no93/n93ori7.htm

6. Mulet Pérez AM, Gámez Escalona MM, Tamayo Ochoa M, Escobar Bernal A, Pozo Allen H, Verdecia Carralero AM. Gastritis crónica antral por Helicobacter pylori y Enfermedad por reflujo gastroesofágico. CCM. 2012 [citado 14 jun 2014]; 16(4). Disponible en: http://www.revcocmed.sld.cu/index.php/cocmed/article/view/522/243

7. Gámez Escalona M, Mulet Pérez A, Miranda Moles Z, Mulet Gámez A. Gastritis crónica antral por Helicobacter pylori en la infancia. Rev Cub Pediatr. 2008 [citado 14 jun 2014]; 80 (1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_pdf&pid=S0034-75312008000100002&lng=es&nrm=iso&tlng=es

8. Escobar Bernal A. Gastropatía por antiinflamatorios no esteroideos e infección por Helicobacter pylori. Hospital Universitario Vladimir Ilich Lenin. Holguín, febrero 2008 a febrero 2009. (Tesis). Holguín: Hospital Docente Vladimir Ilich Lenin; 2010.

9. Laszlo Szabo I, Cseko K, Czimmer J, Mozsik G. Diagnosis of Gastritis. Review from early Pathological evaluation to present day management. En: Current Topics in Gastritis. Hungary: InTech; 2012 [citado 16 jun 2014] Disponible en: http://www.intechopen.com/download/pdf/41544

10. Fenoglio Preiser CM, Noffsinger AE, Stemmermann GN, Lantz PE, Isaacson PG. Gastrointestinal Pathology: An Atlas and Text. 3 ed. Philadelphia: Lippincott Williams & Wilkins; 2008.

11. Hoffman V, Lassalle S, Selva E, Kalem K, Steff A, Hébuterne X, et Al. Involvement of mast cells in gastritis caused by Helicobacter pylori: a potential role in epithelial cell apoptosis. J Clin Pathol. 2007 [citado 16 jun 2014]; 60:600-7. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1955068/pdf/600.pdf

12. Gillen D, Fyfe V, Crabtree JE. CagA and vacA genotypes of Helicobacter pylori isolated from Turkish patients with active or non-active chronic gastritis. Scan J Infect Dis. 2010 [citado 16 jun 2014]; 42(6-7):435-8. Disponible en: http://informahealthcare.com/doi/abs/10.3109/00365540903563418

13. Toljamo K, Niemelä SE, Karvonen AL, Karttunen R, Karttunen TJ. Histopathology of gastric erosions. Association with etiological factors and chronicity. Helicobacter. 2011 [citado 16 jun 2014];16(6):444-51. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1523-5378.2011.00871.x/full

14. Tang CL, Ye F, Liu W, Pan XL, Qian J, Zhang GX. Eradication of Helicobacter pylori infection reduces the incidence of Peptic Ulcer Disease in patients using nonsteroidal anti-inflammatory drugs: A meta-analysis. Helicobacter. 2012 [citado 17 jun 2014]; 17 (4):286-96. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1523-5378.2012.00942.x/pdf

15. Matsushima K, Isomoto H, Inoue N, Nakayama T, Hayashi T, Nakayama M, et al. MicroRNA signatures in Helicobacter pylori-infected gastric mucosa. Int J Cancer. 2011 [citado 18 jun 2014];128(2):361–70. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=MicroRNA+signatures+in+Helicobacter+pylori-infected+gastric+mucosa

16. Tanigawa T, Watanabe T, Higuchi K, Tominaga K, Fujiwara Y, Oshitani N, et Al. Long term use of nonsteroidal anti-inflammatory drugs normalizes the kinetics of gastric epithelial cells in patients with Helicobacter pylori infection via attenuation of gastric mucosal inflammation. J Gastroenterol. 2009 [citado 18 jun 2014]; 44(19):8-17. Disponible en: http://link.springer.com/content/pdf/10.1007%2Fs00535-008-2287-1.pdf

17. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: Importance of cyclooxygenase inhibition and gastric hypermotility. World J Gastroenterol. 2012. [citado 18 jun 2014]; 18(18): 2147-60. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351764/pdf/WJG-18-2147.pdf

18. Varbanova M, Malfertheiner P. Bacterial load and degree of gastric mucosal inflammation in Helicobacter pylori infection. Dig Dis. 2011[citado 18 jun 2014]; 29(6):592-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22179216

19. Hernández Garcés HR. Estómago. Gastropatía por antiinflamatorios no Esteroideos. En: Manual de endoscopia digestiva superior diagnóstica. La Habana: Editorial Ciencias Médicas; 2008. p. 147- 50.

20. Lanas AA, Bajador AE. Gastroenteropatía por AINE. En: Julio Ponce. Tratamiento de las enfermedades gastroenterológicas. 2 ed. Asociación Española de Gastroenterología. Madrid: SCM SL; 2006. p. 121-7.

21. Zhang LJ, Wang SY, Huo XH, Zhu ZL, Chu JK, Ma JC, et al. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World J Gastroenterol. 2009 [citado 20 jun 2014]; 15(22):2731-8. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695888/pdf/WJG-15-2731.pdf

22. Wang J, Wang WH, Li J, Liu FX. Celecoxib inhibits Helicobacter pylori colonization-related factors. World J Gastroenterol. 2010 [citado 20 jun 2014];16(7): 846-53. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825331/pdf/WJG-16-846.pdf

23. Rollán RA. Infección por Helicobacter pylori. En: Weitz VJC, Berger FZ, Sabah TS, Silva CH, Diagnóstico y tratamiento de las enfermedades digestivas. Santiago de Chile: Editorial Iku; 2008. p.113-25.

24. Kiltz U, Zochling J, Schmidt WE, Braun J. Use of NSAIDs and infection with Helicobacter pylori -what does the rheumatologist need to know? Rheumatology. 2008 [citado 21 jun 2014]; 47(9): 1342–7. Disponible en: http://rheumatology.oxfordjournals.org/content/47/9/1342.full.pdf+html